Over 100 Republicans back legal effort to challenge election results

https://youtu.be/om46J9RWfX4

Over 100 Republican lawmakers and 17 GOP state attorneys general are backing a lawsuit at the Supreme Court that seeks to overturn the election results in Georgia, Pennsylvania, Michigan and Wisconsin. Legal experts say the lawsuit, which was filed by Texas Attorney General Ken Paxton, is baseless and unlikely to be heard by the high court. Weijia Jiang reports. Nick Note: this is another even that has the markets on edge. I believe that the odds are 10 to 1 that the Supreme Court will toss this case and the markets will breath a sigh of relief.

Coronavirus relief talks stalled in Congress as deadlines inch closer

Congress is preparing to potentially work through the holidays until they can pass more coronavirus aid for the country. CBS News chief congressional correspondent Nancy Cordes, CBS News political correspondent Ed O’Keefe, and NPR White House correspondent Tamara Keith spoke to “Red and Blue” host Elaine Quijano about where negotiations stand, as well as the latest from the outgoing Trump administration and the incoming Biden transition team. Nick Note: Hang tight their will be a deal!

Stocks Slump, Dollar Rebounds Amid Risk-Off Mood: Markets Wrap

(Bloomberg) — Investors are winding up the week doing risk-off trades, with U.S. stimulus talks hung up and coronavirus developments weighing on sentiment. The dollar rose the most in almost two weeks. European stocks fell more than 1%, as Germany said the continent’s biggest economy had record virus cases and deaths. Sanofi dropped on news that its Covid-19 shot failed to produce a strong enough response in older people. U.S. equity futures sank in the wake of stimulus talks stalling over shielding companies from virus lawsuits. The Cboe Volatility Index, which gauges expected price swings for the S&P 500, headed for the biggest weekly increase since the run-up to the November presidential election.

chart: Volatility has biggest weekly increase since run-up to November election © Bloomberg Volatility has biggest weekly increase since run-up to November election

 

“After the sharp increase in sentiment and positioning in November, continued rises in Covid-19 cases and lockdowns have started to weigh on risky assets,” said Christian Mueller-Glissmann, London-based head of asset allocation at Goldman Sachs Group Inc. “But with our constructive macro outlook for next year, we would not expect a deep correction but more of a consolidation.” Stock markets were choppy this week as the fate of an additional relief package in Washington remained unresolved as Democrats and Republicans continue to negotiate. A disappointing jobs report and a strong 30-year auction of Treasuries on Thursday signaled investor caution over whether fresh economic stimulus will come before year-end. The European Central Bank escalated its efforts to shield the region from a possible double-dip recession with another burst of monetary stimulus, while cautioning that it may not use up all the new firepower. Nick Note: I do not believe this is the end of the bull run. I do believe the market is fretting over the happy check stimulus bill stalling. I still believe their will be a stimulus bill and a vaccine launch and the Republicans will keep control of the senate in the Georgia run off.

FDA panel recommends Pfizer’s COVID-19 vaccine approval

A federal advisory panel on Thursday recommended the emergency use of Pfizer’s COVID-19 vaccine. The Food and Drug Administration is expected to approve the drug, kicking off a massive nationwide operation to get nearly 3 million doses of the vaccine to hospitals and drug stores across the country.  “We’ve been working very closely with our state and local partners to make sure they have plans in place to identify providers that are able to receive, store and use the vaccine,” said Dr. Anita Patel, deputy of the CDC’s vaccine task force.  The experts voted 17 to 4 in favor of recommending the drug for emergency use for people aged 16 years and older, with one of the members withholding. Health care workers and nursing home residents will be among the first to get the vaccine.  Nick Note: I would not be taking a vaccine that i do not know whats in it. I do not apologize for wanting to know EXACTLY what the monkey chromosomes added were. I find it incredible it has not been disclosed and the doctors in the clown car approved this vaccine solely on the disclosures of the manufacturers. I do not apologize for understanding the sequencing. IF YOU WANT TO trust THESE PEOPLE THATS UP TO YOU. I ran out of trust  for big pharma a long time ago!

A lot of progress made on stimulus – Mnuchin

US Treasury Secretary Steven Mnuchin has said that senators from both parties are making progress on stimulus talks and more meetings are scheduled for later on Thursday. House Speaker Nancy Pelosi is set to speak later on. The S&P 500 Index has returned to positive territory after trading lower earlier in the day.  Mnuchin has said that senators from both parties are making progress on stimulus talks and more meetings are scheduled for later on Thursday. House Speaker Nancy Pelosi is set to speak later on. Nick Note: I have been adamant their will be a stimulus deal with happy checks. And And the market does not give a shit about dead baby boomers. Its all about the millennials in the basement smoking pot, playing video games and trading Robin Hood

Stocks Drop, Bonds Rise Amid Stimulus Stalemate: Markets Wrap

(Bloomberg) — Stocks fell on concern that prospects for a stimulus deal remain elusive amid the most-intense negotiations over a Covid-19 package since Election Day. The S&P 500 also dropped after data showed applications for U.S. unemployment benefits surged last week, topping most estimates. Technology shares continued to underperform, with Facebook Inc. slipping further as the U.S. Federal Trade Commission took a major step toward a possible breakup of the social-media giant by filing an antitrust lawsuit. Airbnb Inc. will start trading Thursday after DoorDash Inc. supercharged investor expectations by almost doubling in its frenzied public debut. Senate Majority Leader Mitch McConnell and House Speaker Nancy Pelosi have given no sign yet that they’re ready to directly engage in negotiations to sort through competing pandemic relief proposals — a step that many lawmakers say will be necessary to complete a deal this month. Meanwhile, House Republican Leader Kevin McCarthy told CNBC that he sees a deal done next week. Elsewhere, the euro rose after policy makers escalated their efforts to shield the region from a possible double-dip recession with another burst of monetary stimulus, while cautioning that it may not use up all the new firepower. The pound fell as negotiations between the U.K. and the European Union were seen on course to end without a trade deal. Surges in Doordash Inc. and C3.ai Inc. on the first day of trading were in keeping with rising speculation for U.S. stock investors, according to Jonthan Krinsky, chief market technician at Bay Crest Partners LLC, who cited the Renaissance IPO and IPOX SPAC indexes. Renaissance Capital LLC’s gauge of initial public offerings rose 32% from a late-October low through Tuesday. In a similar period, IPOX Schuster LLC’s index of current and former blank-check companies climbed 40%. The IPO index fell 3.2% Wednesday even as Doordash gained 86% and C3.ai jumped 120%. The SPAC index rose 0.3%. Nick Note: This is a temporary pull back. The big downward move we see coming in the first quarter. Soon the vaccines and stimulus will come and the market will rally again. Remember their is a lot of cash that has got to go into the mraket

More Americans are shoplifting food as aid runs out during the pandemic

The coronavirus recession has been a relentless churn of high unemployment and economic uncertainty. The government stimulus that kept millions of Americans from falling into poverty earlier in the pandemic is long gone, and new aid is still a dot on the horizon after months of congressional inaction. Hunger is chronic, at levels not seen in decades. The result is a growing subset of Americans who are stealing food to survive. Shoplifting is up markedly since the pandemic began in the spring and at higher levels than in past economic downturns, according to interviews with more than a dozen retailers, security experts and police departments across the country. But what’s distinctive about this trend, experts say, is what’s being taken – more staples like bread, pasta and baby formula. “We’re seeing an increase in low-impact crimes,” said Jeff Zisner, chief executive of workplace security firm Aegis. “It’s not a whole lot of people going in, grabbing TVs and running out the front door. It’s a very different kind of crime – it’s people stealing consumables and items associated with children and babies.” With Americans being advised to brace for a difficult winter amid skyrocketing coronavirus infection rates and the economic recovery nearly stalled, the near-term outlook is grim. More than 20 million Americans are on some form of unemployment assistance, and 12 million will run out of benefits the day after Christmas unless new relief materializes. Though lawmakers have made progress this week on a $908 billion bill, details are still being worked out, congressional aides said. Meanwhile, an estimated 54 million Americans will struggle with hunger this year, a 45% increase from 2019, according to the U.S. Department of Agriculture. With food aid programs like SNAP and WIC being reduced, and other federal assistance on the brink of expiration, food banks and pantries are being inundated, reporting hours-long waits and lines that stretch into the thousands. Several federal food programs that have provided billions of dollars in fresh produce, dairy and meat to U.S. food banks also are set to expire at the end of the year. The largest among them, the Farmers to Families Food Box, has provided more than 120 million food boxes during the pandemic and is already running out of funding in many parts of the country. With the United States now registering more than 150,000 new cases a day, some communities are reintroducing restrictions in an effort to contain the virus. Most of California is now under strict stay-at-home orders, for example, while states including Nevada, Maryland and Pennsylvania have issued new indoor occupancy limits. Such orders tend to hit already vulnerable workers in low-wage service jobs in restaurants, retail and bars the hardest. Nearly 26 million adults – or 1 in 8 Americans – reported not having enough food to eat as of mid-November, according to the latest data from the Census Bureau. That figure has climbed steadily during the pandemic, and has hit record highs since the government agency began collecting such data in 1998. Nick Note: As congress fiddles Rome burns.

Ivermectin And Doxycycline To Treat Mild/Moderate COVID-19: Randomized, Double Blinded, Placebo Ctrl

https://youtu.be/5MNsM-ZhRS4

This video we will discuss and review a trial from ClinicalTrials.gov that have reported their results, but not published them. It is a randomized, double blinded, placebo control trial out of Bangladesh comparing treatment with Ivermectin and Doxycycline with standard care (tylenol, vitamin D, steroids as needed, oxygen as needed, etc) versus standard care alone. Their reported results were quite impressive. They reported increased clinical improvement at 7 days, decreased clinical deterioration at 30 days, and decreased viral loads at 14 days in those who received IVM and Doxy! Were there any adverse effects? Check out the video for all the details! Link to the study below:

https://clinicaltrials.gov/ct2/show/r…

Called a Miracle Anti Viral Ivermectin

‘Generic Drug Repurposing for COVID-19” The Israeli Perspective’: Tel Aviv University’s Spark program recently hosted a webinar titled “Generic Drug Repurposing for COVID-19: The Israeli Perspective.” In collaboration with the MedInsight Institute, presenters included Professor Alex Jadad, Faculty of Medicine and School of Public Health, University of Toronto, Canada; Moshe Rogosnitzky, Executive Director, MedInsight Research Institute from both New York and Israel; professor Yaakov Nahmias, Director for the Center of Bio engineering, the Hebrew University of Jerusalem; and Professor Eli Schwartz with Sheba Medical Center, Tel Aviv University, #Israel, who presented the “Sheba #Ivermectin Project (SIP).” Establishing a movement in Israel to consider the repurposing of generic drugs for purposes of economically and forcefully targeting #COVID-19, the drugs discussed in this presentation included Ivermectin, are potentially safe, effective and widely accessible. The organizers of this event are clear for the world to hear: “Of the 9,000 currently approved drugs that exist globally, the potential for overcoming COVID-19 certainly exists.” https://trialsitenews.com/generic-dru… The FLCCC Alliance press conference from Houston, Texas: Some Highlights from the press conference starring the Frontline COVID19 Critical Care Alliance from Houston, Texas to discuss emerging evidence for economical and widely available therapeutic possible options for treating early-stage COVID-19 cases. See the whole press conference here: https://www.youtube.com/watch?v=4V3yx… Great Plains Health Severe COVID-19 Patients Benefit from RLF-100: Recently showcased on local media, North Platte Nebraska’s Great Plains Health (GPH) has treated at least 20 patients with Aviptadil (RLF-100), an investigational product recently submitted for emergency use authorization in late September. One of those surviving patients, Mark Cardenas, went on air to share his experience and thanks for the access. It literally may have saved his life. Produced by a Swiss company called Relief Therapeutics, Great Plains Health infectious disease physician Eduardo Freitas heard about the drug via a network of other physicians. It was through that network that Dr. Freitas was able to secure a communication channel with U.S and Israel-based NeuroRx, the biotechnology company that co develops the drug for commercialization. TrialSite has reported on a few situations in Texas where patients with severe COVID-19 experienced marked improvement thanks to access to the drug opened up by the U.S. Food and Drug Administration via clinical trials and Expanded Access Protocol. It is through the latter that GPH was able to offer the investigational product to select patients facing severe COVID-19 conditions. https://trialsitenews.com/great-plain… Nick Note: Its nothing short of malpractice not to use the Ivermectin

Ivermectin Works For COVID-19 – LATEST STUDIES

https://youtu.be/V4fEBK1inj4

Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019

Link Here: https://doi.org/10.1016/j.chest.2020.10.009

Original in-vitro study about Ivermectin https://www.ncbi.nlm.nih.gov/pmc/arti…

A study from bangladesh found that Ivermectin + Doxyclyclin significantly reduces mortality and morbidity in COVID-19 patients. https://clinicaltrials.gov/ct2/show/s…

A systemic review of the antiviral activity of Ivermectin https://www.nature.com/articles/s4142… https://journal.chestnet.org/article/… PDF for the above study after it was accepted

https://journal.chestnet.org/article/… Pre-print of the above study https://www.medrxiv.org/content/10.11…

A search of various Ivermectin studies for your reading pleasure https://clinicaltrials.gov/ct2/result…

Iota carrageenan and Ivermectin oral drops https://clinicaltrials.gov/ct2/show/r…

Here is a index of the Clinical studies I have reviewed their are 44 of what i call suppressed studies. Think about it big Pharah has been given world wide 250 billion for the various vaccines. The medicines in the studies cost pennies a dose. Big Pharma wins the and over 2 million people dead have lost. they did not have to die:

https://clinicaltrials.gov/ct2/results?cond=Covid19&term=ivermectin&cntry&state&city&dist

Nick Note:  From what i  am seeing the beast results is from the Ft Lauterdale  Florida study as published in the October 12 study was a combination of Ivermectin and hydroxychloroquine and Doxyclyclin seemed to work best…..